Specialty: UK group continues to influence local managed care discussions
Medicare & Reimbursement Advisor Weekly, June 17, 2009
The National Institute for Health and Clinical Excellence (NICE) continues to be an important resource for U.S. managed care, particularly in the specialty pharmacy and oncology arena. This year, the UK government organization approved Revlimid for multiple myeloma (with the condition that Celgene meets the cost of therapy after 26 cycles), and Sutent for kidney cancer, but Alimta was not approved. In recent MRAW editions, we have discussed the role of NICE in managed care decisions. Future issues will include interviews with your plan customers about their views on NICE.
Here is a short list (below) of upcoming guidelines NICE is expected to release in the next 12 months.
Most Popular
- Articles
-
- Don't forget the three checks in medication administration
- Note similarities and differences between HCPCS, CPT® codes
- Practice the six rights of medication administration
- Q&A: Primary, principal, and secondary diagnoses
- What does case-mix index mean to you?
- Nursing responsibilities for managing pain
- Complications from immobility by body system
- Prevent dehydration with nursing interventions
- OB services: Coding inside and outside of the package
- Coding Clinic reiterates guidelines for provider documentation
- E-mailed
-
- Capturing start and stop times for infusions
- Understand the spine to code back procedures correctly
- Safe rooms for suicidal patients
- Q/A: Billing telemetry daily monitoring
- Q&A: Sepsis as a primary diagnosis
- Learn how to read an OP report
- Inpatient-only procedures: Accuracy helps avoid denials, ensure compliance
- Coding, billing, and documentation tips for teaching physicians, interns, residents, and students
- Coding Clinic reiterates guidelines for provider documentation
- Clinical Corner: Revisiting respiratory failure
- Searched
